利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.026 秒)

    PYRIDIN-2-ONVERBINDUNGEN UND DEREN VERWENDUNG ALS MODULATOREN DES DOPAMIN D3 REZEPTORS
    5.
    发明公开
    PYRIDIN-2-ONVERBINDUNGEN UND DEREN VERWENDUNG ALS MODULATOREN DES DOPAMIN D3 REZEPTORS 有权
    吡啶-2-酮化合物及其作为多巴胺D 3受体调节剂的使用

    公开(公告)号：EP1763522A1

    公开(公告)日：2007-03-21

    申请号：EP05761787.0

    申请日：2005-06-03

    申请人： Abbott GmbH & Co. KG

    发明人： GENESTE, Hervé ,  BRAJE, Wilfried ,  HAUPT, Andreas

    IPC分类号： C07D401/12 ,  A61K31/506 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24

    CPC分类号： C07D401/12

    摘要： The invention relates to novel pyridin-2-one compounds of general formula (I), in which A represents a 4- to 6-membered hydrocarbon chain that can have 1 or 2 methyl groups as substituents, wherein 1 or 2 carbon atoms can be replaced by oxygen, a carbonyl group or sulfur, and the hydrocarbon chain can have a double bond or a triple bond; R1, R2, R3 and R4 have the meanings as cited in the claims and in the description. The invention also relates to the tautomers of compounds I, the physiologically acceptable salts of compounds I, and to the physiologically acceptable salts of the tautomers of compounds I. The invention also relates to the use of compounds of general formula (I) and of the tautomers, and to the use of the physiologically acceptable salts of compounds I and of the tautomers for producing a pharmaceutical agent for treating diseases that respond to the influence of dopamine D3 receptor antagonists or agonists.

    KETOLACTAM-VERBINDUNGEN UND IHRE VERWENDUNG
    9.
    发明授权
    KETOLACTAM-VERBINDUNGEN UND IHRE VERWENDUNG 有权
    酮内酰胺化合物及其用途

    公开(公告)号：EP1692129B1

    公开(公告)日：2008-08-20

    申请号：EP04803759.2

    申请日：2004-12-10

    申请人： Abbott GmbH & Co. KG

    发明人： LUBISCH, Wilfried ,  HAUPT, Andreas ,  BRAJE, Wilfried ,  GENESTE, Hervé

    IPC分类号： C07D403/12 ,  C07D401/12 ,  C07D223/16 ,  A61K31/55 ,  A61P13/12 ,  A61P25/28

    CPC分类号： C07D401/12 ,  C07D223/16 ,  C07D403/12

    摘要： The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation of the dopamine D3 receptor. The keto lactams have general formula (I), wherein: (a) represents a group of formulas (b) or (c), wherein D is bound to the nitrogen atom and W, Rp and Rq have the meanings cited in Claim 1; -B- represents a bond or (d), wherein Rm and Rn have the meanings cited in Claim 1; (e) represents a single bond or a double bond; Rv, Rw, Rx and Ry have the meanings cited in Claim 1; D represents a linear or branched 2 to 10-membered alkylene chain that can have, as chain members, a heteroatom group K, which is selected among O, S, S(O), S(O)2, N-R8, CO-O, C(O)NR8 and/or 1 or 2 non-adjacent carbonyl groups and which can have a cycloalkane diyl group and/or a double or triple bond; (f) represents a saturated or monounsaturated monocyclic nitrogen heterocyclic compound having 5 to 8 cyclic members or a bicyclic saturated nitrogen heterocyclic compound having 7 to 12 cyclic members.

    N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR
    10.
    发明授权
    N-[(PIPERAZINYL)HETARYL]ARYLSULFONAMIDE COMPOUNDS WITH AFFINITY FOR THE DOPAMINE D3 RECEPTOR 有权
    N - [（哌嗪基）杂芳基]用亲和对多巴胺D 3受体的芳基磺酰胺衍生物

    公开(公告)号：EP1613596B1

    公开(公告)日：2008-03-12

    申请号：EP04726985.7

    申请日：2004-04-13

    申请人： Abbott GmbH & Co. KG

    发明人： BRAJE, Wilfried ,  HAUPT, Andreas ,  LUBISCH, Wilfried ,  GRANDEL, Roland ,  DRESCHER, Karla, c/o Abbott GmbH & Co. KG ,  GENESTE, Hervé ,  UNGER, Liliane ,  SAUER, Daryl, R. ,  TURNER, Sean, C.

    IPC分类号： C07D213/76 ,  C07D239/48 ,  C07D487/08 ,  C07D213/74 ,  A61K31/44 ,  A61K31/505 ,  A61P13/12 ,  A61P25/18

    CPC分类号： C07D213/74 ,  C07D213/76 ,  C07D239/48 ,  C07D239/50 ,  C07D403/04 ,  C07D403/14 ,  C07D487/08

    摘要： The invention relates to N-[(piperazinyl)hetaryl]arylsulfonamide compounds of the general formula (I ) in which Q is a bivalent, 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Ra which is/are selected, independently of each other, from halogen, CN, NO2, C02R4, COR5, C1-C4-alkyl and C1-C4-haloalkyl; Ar is phenyl or a 6-membered heteroaromatic radical which possesses 1 or 2 N atoms as ring members and which optionally carries one or two substituents Rb, which is/are selected from halogen, NO2, CN, C02R4, COR5, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl and C1-C4-haloalkyl, with it also being possible for two radicals Rb which are bonded to adjacent C atoms of Ar to be together C3-C4-alkylene; R1 is hydrogen, C1-C4-alkyl, C1-C4-haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkyl-C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy-C1-C4-alkyl, C3-C4-alkenyl or C3-C4-alkynyl; with the radicals n, R1, R2, R3, R4 and R5 having the meanings given in the patent claims, to the N-oxides and to the physiologically tolerated acid addition salts of these compounds and to pharmaceutical compositions which comprise at least one N-[(piperazinyl)hetaryl]arylsulfonamide compound as claimed in one of claims 1 to 10 and/or at least one physiologically tolerated acid addition salt of I and/or an N-oxide of I, where appropriate together with physiologically acceptable carriers and/or auxiliary substances for treating diseases which respond to influencing by dopamine D3 receptor antagonists or agonists, in particular for treating diseases of the central nervous system and disturbances of kidney function.